Rosaria Greco

List of Publications by Year
in descending order

70 papers	1,977 citations	172207 29 h-index	276539 41 g-index
70 all docs	70 docs citations	70 times ranked	2209 citing authors

#	Article	IF	Citations
1	The endocannabinoid system and related lipids as potential targets for the treatment of migraineâ€related pain. Headache, 2022, 62, 227-240.	1.8	14
2	Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine. Journal of Headache and Pain, 2022, 23, .	2.5	3
3	Characterization of CB2 Receptor Expression in Peripheral Blood Monocytes of Acute Ischemic Stroke Patients. Translational Stroke Research, 2021, 12, 550-558.	2.3	13
4	Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study. Cephalalgia, 2021, 41, 185-196.	1.8	18
5	Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine. Neurotherapeutics, 2021, 18, 556-568.	2.1	8
6	Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine. Neurobiology of Disease, 2021, 147, 105157.	2.1	29
7	Neuroprotection Following Stroke. , 2021, , .		0
8	Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks. Pain, 2021, 162, 2376-2385.	2.0	8
9	CD163 as a Potential Biomarker of Monocyte Activation in Ischemic Stroke Patients. International Journal of Molecular Sciences, 2021, 22, 6712.	1.8	11
10	Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine. Cells, 2021, 10, 2543.	1.8	19
11	Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally-induced migraine attacks. Journal of the Neurological Sciences, 2021, 429, 117721.	0.3	0
12	Expression of Selected microRNAs in Migraine: A New Class of Possible Biomarkers of Disease?. Processes, 2021, 9, 2199.	1.3	6
13	FAAH inhibition as a preventive treatment for migraine: A pre-clinical study. Neurobiology of Disease, 2020, 134, 104624.	2.1	33
14	Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?. Journal of Headache and Pain, 2020, 21, 122.	2.5	28
15	Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study. Cephalalgia, 2020, 40, 1336-1345.	1.8	14
16	Migraine neuroscience: from experimental models to target therapy. Neurological Sciences, 2020, 41, 351-361.	0.9	7
17	Nitroglycerin as a comparative experimental model of migraine pain: From animal to human and back. Progress in Neurobiology, 2019, 177, 15-32.	2.8	76
18	Azithromycin Affords Neuroprotection in Rat Undergone Transient Focal Cerebral Ischemia. Frontiers in Neuroscience, 2019, 13, 1256.	1.4	15

#	Article	IF	Citations
19	Gender Differences in the Clinical Presentation of Cluster Headache: A Role for Sexual Hormones?. Frontiers in Neurology, 2019, 10, 1220.	1.1	27
20	The endocannabinoid system in migraine: from bench to pharmacy and back. Current Opinion in Neurology, 2019, 32, 405-412.	1.8	19
21	Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemiaâ€reperfusion injury. Journal of Neuroscience Research, 2018, 96, 151-159.	1.3	23
22	Inhibition of monoacylglycerol lipase: Another signalling pathway for potential therapeutic targets in migraine?. Cephalalgia, 2018, 38, 1138-1147.	1.8	12
23	Antagonism of Transient Receptor Potential Ankyrin Type-1 Channels as a Potential Target for the Treatment of Trigeminal Neuropathic Pain: Study in an Animal Model. International Journal of Molecular Sciences, 2018, 19, 3320.	1.8	32
24	Endocannabinoid System and Migraine Pain: An Update. Frontiers in Neuroscience, 2018, 12, 172.	1.4	48
25	Paradigm Shift to Neuroimmunomodulation for Translational Neuroprotection in Stroke. Frontiers in Neuroscience, 2018, 12, 241.	1.4	17
26	Chronic and intermittent administration of systemic nitroglycerin in the rat induces an increase in the gene expression of CGRP in central areas: potential contribution to pain processing. Journal of Headache and Pain, 2018, 19, 51.	2.5	42
27	Antinociceptive effect of inhalation of the essential oil of bergamot in mice. FÃ¬toterapÃ¬Ã¢, 2018, 129, 20-24.	1.1	37
28	Polarization of Microglia/Macrophages in Brain Ischaemia: Relevance for Stroke Therapy. Springer Series in Translational Stroke Research, 2017, , 303-328.	0.1	0
29	Modulation of cerebral RAGE expression following nitric oxide synthase inhibition in rats subjected to focal cerebral ischemia. European Journal of Pharmacology, 2017, 800, 16-22.	1.7	11
30	Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms. Cephalalgia, 2017, 37, 1272-1284.	1.8	39
31	Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson's Disease. Frontiers in Neuroscience, 2017, 11, 306.	1.4	58
32	The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model. Journal of Headache and Pain, 2017, 18, 94.	2.5	50
33	Andrographis Paniculata shows anti-nociceptive effects in an animal model of sensory hypersensitivity associated with migraine. Functional Neurology, 2016, 31, 53-60.	1.3	9
34	P007. Inhibition of monoacylglycerol lipase activity modulates the activation of brain structures relevant for migraine pathogenesis. Journal of Headache and Pain, 2015, 16, A165.	2.5	0
35	Evaluation of ADMA-DDAH-NOS axis in specific brain areas following nitroglycerin administration: study in an animal model of migraine. Journal of Headache and Pain, 2015, 16, 560.	2.5	31
36	Endocannabinoids and migraine. , 2015, , 173-189.		1

#	Article	IF	Citations
37	Effects of peripheral FAAH blockade on NTG-induced hyperalgesiaâ€"evaluation of URB937 in an animal model of migraine. Cephalalgia, 2015, 35, 1065-1076.	1.8	50
38	Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects. Stem Cells Translational Medicine, 2015, 4, 1073-1085.	1.6	52
39	Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. European Journal of Pharmacology, 2014, 744, 91-97.	1.7	19
40	Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. Journal of Headache and Pain, 2014, 15, 14.	2.5	30
41	Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: An observational study. Diabetes Research and Clinical Practice, 2014, 103, 292-297.	1.1	24
42	Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia, 2014, 34, 594-604.	1.8	64
43	Severity of Demographic and Clinical Characteristics, Revascularization Feasibility, Major Amputation, and Mortality Rate in Diabetic Patients Admitted to a Tertiary Diabetic Foot Center for Critical Limb Ischemia: Comparison of 2 Cohorts Recruited at a 10-year Distance. Annals of Vascular Surgery, 2014, 28, 1729-1736.	0.4	5
44	Effect of Sex and Estrogens on Neuronal Activation in an Animal Model of Migraine. Headache, 2013, 53, 288-296.	1.8	39
45	Transdermal Hormonal Therapy in Perimenstrual Migraine: Why, When and How?. Current Pain and Headache Reports, 2012, 16, 467-473.	1.3	17
46	Modulation of RAGE Isoforms Expression in the Brain and Plasma of Rats Exposed to Transient Focal Cerebral Ischemia. Neurochemical Research, 2012, 37, 1508-1516.	1.6	17
47	IkappaB-alpha expression following transient focal cerebral ischemia is modulated by nitric oxide. Brain Research, 2011, 1372, 145-151.	1.1	24
48	Effects of anandamide in migraine: data from an animal model. Journal of Headache and Pain, 2011, 12, 177-183.	2.5	38
49	Temporal profile of vascular changes induced by systemic nitroglycerin in the meningeal and cortical districts. Cephalalgia, 2011, 31, 190-198.	1.8	36
50	Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. Cephalalgia, 2010, 30, 296-302.	1.8	52
51	The endocannabinoid system and migraine. Experimental Neurology, 2010, 224, 85-91.	2.0	58
52	Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. Neuroscience Letters, 2009, 467, 203-207.	1.0	75
53	Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia. Brain Research, 2008, 1238, 215-223.	1.1	28
54	Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia, 2008, 28, 114-26.	1.8	58

#	Article	IF	Citations
55	Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat. , 2008, , 219-222.		0
56	A Role for Brain Cyclooxygenaseâ€2 and Prostaglandinâ€E2 in Migraine: Effects of Nitroglycerin. International Review of Neurobiology, 2007, 82, 373-382.	0.9	36
57	Neuroprotective Effect of Nitroglycerin in a Rodent Model of Ischemic Stroke: Evaluation of Bclâ€2 Expression. International Review of Neurobiology, 2007, 82, 423-435.	0.9	21
58	Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. Brain Research, 2007, 1176, 53-61.	1.1	34
59	Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat. Experimental Neurology, 2006, 200, 240-244.	2.0	1
60	Prostaglandins, glutamate and nitric oxide synthase mediate nitroglycerin-induced hyperalgesia in the formalin test. European Journal of Pharmacology, 2006, 534, 103-107.	1.7	40
61	Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat. Brain Research, 2006, 1101, 145-150.	1.1	7
62	Parthenolide is the Component of Tanacetum Parthenium that Inhibits Nitroglycerin-Induced Fos Activation: Studies in an Animal Model of Migraine. Cephalalgia, 2005, 25, 612-621.	1.8	76
63	Comparative analysis of the neuronal activation and cardiovascular effects of nitroglycerin, sodium nitroprusside and l-arginine. Brain Research, 2005, 1051, 17-24.	1.1	20
64	Effects of acute and chronic restraint stress on nitroglycerin-induced hyperalgesia in rats. Neuroscience Letters, 2005, 383, 7-11.	1.0	63
65	Activation of the Transcription Factor NF-Îºb in the Nucleus Trigeminalis Caudalis in an Animal Model of Migraine. NeuroToxicology, 2005, 26, 795-800.	1.4	49
66	Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. Journal of Chemical Neuroanatomy, 2004, 27, 23-32.	1.0	32
67	Nitroglycerin induces hyperalgesia in ratsâ€"a time-course study. European Journal of Pharmacology, 2003, 464, 159-162.	1.7	98
68	Selective stimulation of striatal dopamine receptors of the D1- or D2-class causes opposite changes of fos expression in the rat cerebral cortex. European Journal of Neuroscience, 2003, 17, 763-770.	1.2	23
69	Central Components of the Analgesic/Antihyperalgesic Effect of Nimesulide. Drugs, 2003, 63, 9-22.	4.9	31
70	Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. Neurological Sciences, 2002, 23, s57-s58.	0.9	2